Crossmark

Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China

Crossref DOI link: https://doi.org/10.1186/s12876-019-0981-5

Published Online: 2019-05-02

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sun, Jian

Ding, Huiguo

Chen, Guofeng

Wang, Guiqiang

Wei, Lai

Zhang, Jiming

Xie, Qing

Wan, Mobin

Tang, Hong

Chen, Shijun

Gao, Zhiliang

Wang, Yuming

Zhang, Dazhi

Huang, Wenxiang

Sheng, Jifang

Ning, Qin

Yang, Dongliang

Lu, Jian

Pan, Chen

Yang, Yuxiu

Wang, Jue

Sun, Chuanzhen

Wang, Qixin

Hou, Jinlin
Funding

Funding for this research was provided by:

Merck Sharp & Dohme, Shanghai, China (N/A)
License Information

Text and Data Mining valid from 2019-05-02
More Information

Article History

Received: 23 January 2018

Accepted: 8 April 2019

First Online: 2 May 2019

Ethics approval and consent to participate

: This study was conducted in accordance with the guidelines of the Declaration of Helsinki and the principles of Good Clinical Practice (ICH-E6). Written informed consent according to standards of the local ethics committees was obtained from all patients.

: Not applicable.

: Qinxin Wang, Jue Wang, and Chuanzhen Sun are employees of MSD China.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below